Anton Mikhailovich Safonov

This study identifies APOBEC3 mutagenesis as a common driver of therapy resistance in breast cancer, associated with poorer clinical outcomes.

The paper identifies a higher prevalence of NF1 pathogenic variants using a genotype-first approach, finding many cases with somatic mosaicism and increased cancer risk.

The paper identifies how germline and somatic mutations interact to cause resistance to CDK4/6 inhibitors in breast cancer and proposes a sequential treatment strategy using PARP inhibitors.

The paper develops a method to detect co-mutated pathways in cancer samples and identifies enriched pathway pairs across six cancer types, suggesting potential mechanisms for immune evasion.